Naproxen NDC 90096-161

NDC codes

FDA NDC Directory

Product NDC (as listed)90096-161Labeler and product segments. Claims need a package NDC.

Product NDC at billing width90096-0161Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
90096-161-01	90096016101	100 TABLET, DELAYED RELEASE in 1 BOTTLE (90096-161-01)Marketed from Aug 31, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Naproxen
Generic name (nonproprietary): naproxen
Active ingredients: Naproxen — 500 mg/1
Dosage form: Tablet, Delayed release
Route: Oral
Labeler: Zameer Pharmaceuticals LLC
Product type: Prescription drug
Marketing category: NDA authorized genericApplication NDA 020067
Marketing start: Aug 31, 2025
Listing expires: Dec 31, 2026
Other FDA classes: Non-Steroidal (Chemical structure)Cyclooxygenase Inhibitors (Mechanism)
Identifiers: Product ID 90096-161_1e574b03-a038-453b-b84f-9437fc2df0f8SPL ID 1e574b03-a038-453b-b84f-9437fc2df0f8SPL set ID d2e5553a-7c90-407c-9f07-3be65560c23aRxCUI 311915UNII 57Y76R9ATQ
Pharmacologic class: Nonsteroidal Anti-inflammatory Drug

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N490096016101 followed by a unit qualifier and the quantity

Package 90096-0161-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 23, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

NAPROXEN Tablets, Naproxen Delayed-Release Tablets, and NAPROXEN SODIUM are indicated for: the relief of the signs and symptoms of: • rheumatoid arthritis • osteoarthritis • ankylosing spondylitis • Polyarticular Juvenile Idiopathic Arthritis NAPROXEN Tablets and NAPROXEN SODIUM are also indicated for: the relief of signs and symptoms of: • tendonitis • bursitis • acute gout the management of: • pain • primary dysmenorrhea

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)